Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®)

2015

• We report the second dystonia patient worldwide who developed secondary treatment failure under therapy with Xeomin.

Keywords:

References

Citations